Semaglutide
medicationA GLP-1 medication that reduces appetite, approved for weight management and type 2 diabetes.
Cagrilintide is a peptide that is research only, not approved for human use in the US.
Also known as AM833, cagrilintide semaglutide, CagriSema
Cagrilintide copies amylin, a hormone involved in fullness and stomach emptying. Novo Nordisk is studying it alone and in CagriSema, but products sold online are not the clinical-trial product.

Not approved for human use in the US. We list it so you can learn what it is, but we do not link to anyone selling it. Not FDA-approved and not lawfully available for personal use. Legitimate access is limited to clinical research.
As of September 28, 2026.
Human trials exist, including late-stage studies, but FDA has not completed a safety and effectiveness review.
These save with the compound when you add it to My Journal, so they’re on the printout for your visit.
Cagrilintide is not approved for human use, so DiscoverMedica links to no seller.
We don’t link to sellers of research-only compounds. Products sold “for research use only” are not made for people and are not held to pharmaceutical quality standards.
Educational information only, not medical advice. It does not replace a conversation with a licensed clinician.
A GLP-1 medication that reduces appetite, approved for weight management and type 2 diabetes.
A weekly GIP and GLP-1 medication approved for weight management, sleep apnea and type 2 diabetes.
An older, daily GLP-1 injection for weight management and diabetes, now available as a generic.
A cheap, decades-old diabetes pill that some people ask about for weight and healthy aging.